Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort
Author
dc.contributor.author
Shinjo, Samuel K.
Author
dc.contributor.author
Bonfá, Eloísa
Author
dc.contributor.author
Wojdyla, Daniel
Author
dc.contributor.author
Borba, Eduardo F.
Author
dc.contributor.author
Ramirez, Luis A.
Author
dc.contributor.author
Scherbarth, Hugo R.
Author
dc.contributor.author
Tavares Brenol, João C.
Author
dc.contributor.author
Chacón Díaz, Rosa
Author
dc.contributor.author
Neira, Oscar J.
Author
dc.contributor.author
Berbotto, Guillermo A.
Author
dc.contributor.author
De La Torre, Ignacio Garcia
Author
dc.contributor.author
Acevedo Vásquez, Eduardo
Author
dc.contributor.author
Massardo, Loret
Admission date
dc.date.accessioned
2019-03-11T12:59:14Z
Available date
dc.date.available
2019-03-11T12:59:14Z
Publication date
dc.date.issued
2010
Cita de ítem
dc.identifier.citation
Arthritis and Rheumatism, Volumen 62, Issue 3, 2018, Pages 855-862
Identifier
dc.identifier.issn
15290131
Identifier
dc.identifier.issn
00043591
Identifier
dc.identifier.other
10.1002/art.27300
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164957
Abstract
dc.description.abstract
Objective. To evaluate the beneficial effect of antimalarial treatment on lupus survival in a large, multiethnic, international longitudinal inception cohort. Methods. Socioeconomic and demographic characteristics, clinical manifestations, classification criteria, laboratory findings, and treatment variables were examined in patients with systemic lupus erythematosus (SLE) from the Grupo Latino Americano de Estudio del Lupus Eritematoso (GLADEL) cohort. The diagnosis of SLE, according to the American College of Rheumatology criteria, was assessed within 2 years of cohort entry. Cause of death was classified as active disease, infection, cardiovascular complications, thrombosis, malignancy, or other cause. Patients were subdivided by antimalarial use, grouped according to those who had received antimalarial drugs for at least 6 consecutive months (user) and those who had received antimalarial drugs for <6 consecutive months or who had never received antimalarial drugs (nonuser). Results